Opioid Addicted Buprenorphine Injectors: Drug Use During and After 12-Weeks of Buprenorphine-Naloxone or Methadone in the Republic of Georgia

Journal of Substance Abuse Treatment

Volumn 50, Issue , 2015, Pages 32-37

  Piralishvili, Gvantsa ^a   Otiashvili, David ^b   Sikharulidze, Zura ^c   Kamkamidze, George ^d   Poole, Sabrina ^e   Woody, George E ^e  

^a Centre for Mental Health and Prevention of Addiction   (United States)

^b Alternative Georgia   (United States)

^c Medical Centre Uranti   (United States)

^d Health research Union   (United States)

^e TREATMENT RESEARCH INSTITUTE   (United States)

Author keywords

Buprenorphine naloxone; Methadone; Non opioid drug use; Opioid substitution therapy

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; ILLICIT DRUG; METHADONE; OPIATE; NALOXONE; NARCOTIC AGENT;

ADDICTION SEVERITY INDEX; ADULT; ARTICLE; DRUG USE; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; UNITED STATES; URINALYSIS; CONTROLLED STUDY; COUNSELING; GEORGIA (REPUBLIC); MIDDLE AGED; OPIOID-RELATED DISORDERS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; BUPRENORPHINE; COUNSELING; DRUG USERS; FEMALE; GEORGIA (REPUBLIC); HUMANS; METHADONE; MIDDLE AGED; NALOXONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 84921416733     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.10.003     Document Type: Article

References (52)

1. Aitken C.K., Higgs P.G., Hellard M.E. Buprenorphine injection in Melbourne, Australia-An update. Drug and Alcohol Review 2008, 27(2):197-199.
2. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence 2007, 88(1):75-78.
3. Bobrovsky O.B.L., Eschenko O., Hayovych Y., Kobyschcha Y., Bobrovsky O.B.L., Eschenko O., et al. Ukraine harmonized AIDS respose progress report 2012, International HIV/AIDS Alliance In Ukraine, Kiev. S.R.M. Bezimenna (Ed.).
4. Bruce D.R., Dvoryak S., Sylla L., Altice F.L. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-Programme description and policy implications. The International Journal on Drug Policy 2007, 18:326-328.
5. Carrieri M.P., Amass L., Lucas G., Vlahov D., Wodak A., Woody G.E. Buprenorphine use: The international experience. Clinical Infectious Diseases 2006, 43:S197-S215. (SUPPLEMENT ARTICLE).
6. Chen K.W., Berger C.C., Forde D.P., D'Adamo C., Weintraub E., Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011, 11:90.
7. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death before and after opiate substitution treatment in primary care: Prospective observational study in UK general practice research database. BMJ 2010, 341:c5475.
8. Craig R.J., Olson R.E. Predicting methadone maintenance treatment outcomes using the addiction severity index and the MMPI-2 content scales. The American Journal of Drug and Alcohol Abuse 2004, 24:1-13.
9. Degenhardt L., Bucello C., Mathers B., Briegleb C., Hammad A., Hickman M. Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies. Addiction 2010, 106:32-51.
10. Dvoriak S., Karachevsky A., Chhatre S., Booth R., Metzger D., Joseph J., et al. Methadone maintenance for HIV positive and HIV negative patients in Kiev: Acceptability and treatment response. Drug and Alcohol Dependence 2013, (in press).
11. Dvoryak S., Grishayeva I. First experience of opioid therapy with buprenorphine in Ukraine. Heroin Addiction and Related Clinical Problems 2008, 10:31-35. (Http://Www.Ukraids.Gov.Ua/Attachments/Article/544/Stm 01.01.13.Xls).
12. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews (Online) 2003, (3):CD002208.
13. Fairbank J.A., Dunteman G.H., Condelli W.S. Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. The American Journal of Drug and Alcohol Abuse 1993, 19(4):465-474.
14. Gambashidze N., Sikharulidze Z., Piralishvili G., Gvakharia N. Evaluation of pilot methadone maintenance therapy in Georgia (Caucasus). Georgian Medical News 2008, 7-8(160-161):25-30. (PMID:18711233[PubMed - indexed for MEDLINE] Evaluation of pilot methadone maintenance therapy in Georgia (Caucasus)).
15. Gamkrelidze A., Javakhishvili J., Kariauli D., Lejava G., Stvilia K., Todadze K., et al. Drug situation in Georgia-2003. Southern Caucasus Anti-Drug Programm, Tbilisi, Georgiae 2004.
16. Gollnisch G. Multiple predictors of illicit drug use in methadone maintenance clients. Addictive Behaviors 1997, 22:353-366.
17. Golovanevskaya M., Vlasenko L., Saucier R. In control? Ukrainian opiate substitution treatment patients strive for a voice in their treatment. Substance Use & Misuse 2012, 47:511-521.
18. Gowing L., Farrell M.F., Bornemann R., Sullivan L.E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2011, 8:CD004145.
19. Hubbard R.L., Marsden M.E., Rachal J.V., Harwood H.J., Cavanaugh E.R., Ginzburg H.M. Drug abuse treatment: A national study of effectiveness 1989, University of North Carolina Press, Chapel Hill.
20. Javakhishvili J., Kariauli D., Lejava G., Stvilia K., Todadze K., Tsintsadze M. Drug situation in Georgia-2005 2006, Southern Caucasus Anti-Drug Programme, Tbilisi, Georgia.
21. Kimber J., Copeland L., Hickman M., Macleod J., McKenzie J., De Angelis D., et al. Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010, 341:c3172.
22. Lawrinson P., Ali R., Buavirat A., Chiamwongpaet S., Dvoryak S., Habrat B., et al. Key findings from the Who collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction 2008, 103:1484-1492.
23. Li Jianhua, Luojian Ms, Chunming Zhang Qualitative research & analysis report on amphetamine type stimulants use situation in Chengdu City, Sichuan, China. Community Action for Harm Reduction Project 2012, International HIV/AIDS Alliance(UK) Kunming Office, (http://www.cahrproject.org/wp-content/uploads/2012/06/Stimulant-Drug-Use-Qualitative-Research-report.pdf).
24. MacArthur G.J., Minozzi S., Martin N., Vickerman P., Deren S., Bruneau J., et al. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ 2012, 345:e5945. 10.1136/bmj.e5945.
25. Malta M., Strathdee S.A., Magnanini M.M.F., Bastos F.I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction 2008, 103:1242-1257.
26. Maremmani I., Pani P.P., Pacini M., Perugi G. Substance use and quality of life over 12months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. Journal of Substance Abuse Treatment 2007, 33(1):91-98.
27. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta- analysis. Addiction 1998, 93:515-532.
28. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic 2003, 2.
29. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2007, 4.
30. Mattick R.P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, (2):CD002207. 10.1002/14651858.CD002207.pub4.
31. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The Fifth Edition of the Addiction Severity Index. Journal of Substance Abuse Treatment 1992, 9(3):199-213. [Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.].
32. Methadone research Web Guide and tutorial NIDA International Program. Part B http://international.drugabuse.gov/educational-opportunities/certificate-programs/methadone-research-web-guide/part-b/question-6-what-e.
33. NICE technology appraisal guidance 114 TA114 Drug misuse-Methadone and buprenorphine for the management of opioid dependence 2010.
34. Nyamathi A., Cohen A., Marfisee M., Shoptaw S., Greengold B., de Castro V., et al. Correlates of alcohol use among methadone-maintained adults. Drug and Alcohol Dependence 2009, 101(1-2):124-127.
35. Otiashvili D., Piralishvili G., Sikharulidze Z., Kamkamidze G., Poole S., Woody G.E. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial. Drug and Alcohol Dependence 2013, 133(2):376-382.
36. Otiashvili D., Srosi P., Somogyi G. Drug control in Georgia: Drug testing and the reduction of drug use? 2008, The Beckley Foundation Drug Policy Program, Briefing Paper Oxford, (15).
37. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanidze M., Miovsky M. Why do the clients of Georgian needle exchange programmes inject buprenorphine?. European Addiction Research 2010, 16(1):1-8.
38. Piralishvili G., Gamkrelidze I., Nikolaishvili N., Chavchanidze M. Evaluation of the quality of life (WHOQOL-BREF) among methadone and suboxone substitution state program patients and healthy volunteers in Georgia. Georgian Medical News 2012, 12(213):44-47.
39. Piralishvili G., Gamkrelidze I., Nikolaishvili N., Chavchanidze M. Needs assessment and treatment compliance at State Opioid Substitution treatment (OST) programmes in Georgia. Georgian Medical News 2013, 1(214):28-32.
40. Powers K.I., Anglin M.D. Cumulative versus stabilizing effects of methadone maintenance. Evaluation Review 1993, 17(3):243-270.
41. Sherman S.G., Sutcliffe C.G., German D., Sirirojn B., Aramrattana A., Celentano D.D. Patterns of risky behaviors associated with methamphetamine use among young Thai adults: A latent class analysis. The Journal of Adolescent Health: official publication of the Society for Adolescent Medicine 2009, 44(2):169-175.
42. Sobell L.C., Sobell M.B. Timeline follow-back: A technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption 1992, The Human Press Inc. R. Litten, J. Allen (Eds.).
43. Srivastava A., Kahan M., Ross S. The effect of methadone maintenance treatment on alcohol consumption: A systematic review. Journal of Substance Abuse Treatment 2008, 34:215-223.
44. Stenbacka M., Beck O., Leifman A., Romelsjö A., Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug and Alcohol Review 2007, 26(1):55-63.
45. Suntharasamai P., Martin M., Vanichseni S., van Griensven F., Mock P.A., Pitisuttithum P., et al. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 2009, 104:235-242.
46. Tilson H., Aramrattana A., Bozzette S.A., Celentano D.D., Falco M., Hammett T.M., et al. Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence 2007, Institute of Medicine, Washington.
47. Methadone maintenance treatment and other opioid replacement therapies 1998, 17-57. Amsterdam7 Harwood Academic Publishers. J. Ward, R.P. Mattick, W. Hall (Eds.).
48. Wasserman D.A., Weinstein M.G., Havassy B.E., Hall S.M. Factors associated with lapses to heroin use during methadone maintenance. Drug and Alcohol Dependence 1998, 52:183-192.
49. Winslow M., Ng W.L., Mythily S., Song G., Yiong H.C. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore. Annals of the Academy of Medicine, Singapore 2006, 35(7):451-456.
50. Winstock A.R., Lea T., Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. The International Journal on Drug Policy 2008, 19(6):450-458.
51. World Health Organization Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence 2009, 136.
52. Zule W.A., Costenbader E.C., Meyer W.J., Wechsberg W.W. Methamphetamine use and risky sexual behaviors during heterosexual encounters. Sexually Transmitted Diseases 2007, 34(9):689-694.